Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3947-3949

  Wagenlehner, Florian M E ^a   Kinzig Schippers, Martina ^b   Tischmeyer, Uwe ^a   Wagenlehner, Christine ^a   Sörgel, Fritz ^b,c   Naber, Kurt G ^a  

^a Urologische Klinik   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; HUMAN; HUMAN EXPERIMENT; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; STAPHYLOCOCCUS; SUSTAINED DRUG RELEASE; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; OFLOXACIN; PROTEUS MIRABILIS; STAPHYLOCOCCUS; URINE;

EID: 33750577894     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00477-06     Document Type: Article

References (28)

1. Anderson, G. G., S. M. Martin, and S. J. Hultgren. 2004. Host subversion by formation of intracellular bacterial communities in the urinary tract. Microbes Infect. 6:1094-1101.
2. Andes, D., and W. A. Craig. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268.
3. Ando, E., K. Monden, R. Mitsuhata, R. Kariyama, and H. Kumon. 2004. Biofilm formation among methicillin-resistant Staphylococcus aureus isolates from patients with urinary tract infection. Acta Med. Okayama 58:207-214.
4. Bokranz, W., X. Wang, H. Tschape, and U. Romling. 2005. Expression of cellulose and curli fimbriae by Escherichia coli isolated from the gastrointestinal tract. J. Med. Microbiol. 54:1171-1182.
5. Debbia, E. A., M. Dolcino, A. Marchese, A. Piazzi, and A. Berio. 2004. Enhanced biofilm production in pathogens isolated from patients with rare metabolic disorders. New Microbiol. 27:361-367.
6. Drobot, G. R., J. A. Karlowsky, D. J. Hoban, and G. G. Zhanel. 1996. Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 40:237-240.
7. Goto, T., Y. Nakame, M. Nishida, and Y. Ohi. 1999. Bacterial biofilms and catheter in experimental urinary tract infection. Int. J. Antimicrob. Agents 11:227-231, 237-239.
8. Jansen, A. M., V. Lockatell, D. E. Johnson, and H. L. Mobley. 2004. Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation. Infect. Immun. 72:7294-7305.
9. Justice, S. S., C. Hung, J. A. Theriot, D. A. Fletcher, G. G. Anderson, M. J. Footer, and S. J. Hultgren. 2004. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. USA 101:1333-1338.
10. Kumon, H. 2000. Management of biofilm infections in the urinary tract. World J. Surg. 24:1193-1196.
11. Lubasch, A., I. Keller, K. Borner, P. Koeppe, and H. Lode. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
12. Meagher, A. K., A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag. 2004. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. 48:2061-2068.
13. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
14. Naber, C. K., M. Hammer, M. Kinzig-Schippers, C. Sauber, F. Sorgel, E. A. Bygate, A. J. Fairless, K. Machka, and K. G. Naber. 2001. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob. Agents Chemother. 45:3524-3530.
15. Naber, K. 1997. Antibacterial activity of antibacterial agents in urine: an overview of applied methods, p. 74-83. In T. Bergan (ed.), Urinary tract infections, vol. 1. Karger, Basel, Switzerland.
16. Naber, K. G., U. Theuretzbacher, M. Kinzig, O. Savov, and F. Sorgel. 1998. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob. Agents Chemother. 42:1659-1665.
17. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution in antimicrobial susceptibility tests for bacteria that grow aerobically. Approved guideline. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
19. Nickel, J. C., M. E. Olson, and J. W. Costerton. 1991. Rat model of experimental bacterial prostatitis. Infection 19(Suppl. 3):S126-S130.
20. Sabbuba, N. A., E. Mahenthiralingam, and D. J. Stickler. 2003. Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J. Clin. Microbiol. 41:4961-4965.
21. Schentag, J. J., K. K. Gilliland, and J. A. Paladino. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1):S39-S46.
22. Seno, Y., R. Kariyama, R. Mitsuhata, K. Monden, and H. Kumon. 2005. Clinical implications of biofilm formation by Enterococcus faecalis in the urinary tract. Acta Med. Okayama 59:79-87.
23. Talan, D. A., K. G. Naber, J. Palou, and D. Elkharrat. 2004. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int. J. Antimicrob. Agents 23(Suppl. 1):S54-S66.
24. Wagenlehner, F. M., M. Kinzig-Schippers, U. Tischmeyer, C. Wagenlehner, F. Sorgel, A. Dalhoff, and K. G. Naber. 2006. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int. J. Antimicrob. Agents 27:7-14.
25. Wagenlehner, F. M., A. Niemetz, A. Dalhoff, and K. G. Naber. 2002. Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000. Int. J. Antimicrob. Agents 19:557-564.
26. Wagenlehner, F. M., S. Wydra, H. Onda, M. Kinzig-Schippers, F. Sorgel, and K. G. Naber. 2003. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob. Agents Chemother. 47:3789-3794.
27. Zhanel, G. G., I. D. Kirkpatrick, D. J. Hoban, A. M. Kabani, and J. A. Karlowsky. 1998. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2427-2430.
28. Zogaj, X., W. Bokranz, M. Nimtz, and U. Romling. 2003. Production of cellulose and curli fimbriae by members of the family Enterobacteriaceae isolated from the human gastrointestinal tract. Infect. Immun. 71:4151-4158.